The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Bone Marrow Transplantation

Volumn 47, Issue 3, 2012, Pages 380-386

  Abelsson, J ^a   Merup, M ^b   Birgegard G ^c   WeisBjerrum, O ^d   Brinch, L ^e   Brune, M ^f   Johansson, P ^a,f   Kauppila, M ^g   Lenhoff, S ^h   Liljeholm, M ⁱ   Malm, C ^j   Remes, K ^g   Vindelov L ^d   Andreasson B ^a,f  

^a NU Hospital Organization   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^j Regionsjukhuset I Linköping ^*  (Sweden)

more..

Author keywords

complications; MAC; myelofibrosis; RIC; survival

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLEEDING; CAUSE OF DEATH; CHILD; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT FAILURE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; FINLAND; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; NORWAY; PRIMARY MYELOFIBROSIS; SWEDEN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84858080528     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.91     Document Type: Article

References (22)

1. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008; 80: 386-390. (Pubitemid 351503104)
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
3. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini Met al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-761. (Pubitemid 39482529)
4. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 219-230.
5. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-2970. (Pubitemid 29415257)
6. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097. (Pubitemid 47281402)
7. Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367-373. (Pubitemid 44484845)
8. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 2004; 256: 161-165. (Pubitemid 38998263)
9. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018. (Pubitemid 26333326)
10. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]. Med Clin (Barc) 1997; 109: 651-655. (Pubitemid 128530840)
11. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973-977. (Pubitemid 40170863)
12. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918. (Pubitemid 37486970)
13. Gupta V, Kroger N, Aschan J, Xu W, Leber B, Dalley C et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 2009; 44: 317-320.
14. EBMT Available from http://www.ebmt.org.
15. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood 2009; 113: 2895-2901.
16. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
17. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119. (Pubitemid 40656163)
18. McClune BL, Weisdorf DJ, Pedersen TL, Tunesda Silva GT, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-1887.
19. Hemmati PG, Terwey TH, Massenkeil G, le Coutre P, Vuong LG, Neuburger S et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. Int J Hematol 2010; 91: 436-445.
20. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Blood 2009; 114: 5264-5270.
21. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
22. van Besien K, Deeg HJ. Hematopoietic stem cell transplantation for myelofibrosis. Semin Oncol 2005; 32: 414-421. (Pubitemid 41073754)